Olympus (7733) Q2 2026 earnings summary

Executive summary

• Medium-term plan targets gradual revenue growth: 3% in year one, 4% in year two, and 5% in year three, aiming to match or exceed mid-single-digit market growth rates over time.

• 2Q FY2026 results were largely in line with forecasts, with no change to full-year guidance as further recovery is expected in the second half.

• Focus on innovation-driven growth, new product launches (e.g., EDOF scopes, EVIS X1, Bronchoscope, OLYSENSE), and external partnerships to drive future performance.

• Restructuring includes a 2,000 position reduction and a shift to a division-led operating model to enhance efficiency and accountability.

• Achieved strong growth in emerging markets by expanding market reach and access capabilities.

Financial highlights

• Margin improvement targeted at 100 basis points per year, aiming for 19% adjusted operating profit by FY2029, with a longer-term aspiration to reach or exceed 20%.

• 2Q revenue: ¥247.8B, up 4% year-over-year after FX adjustment; 6-month revenue: ¥454.4B, down 2% year-over-year after FX adjustment.

• Adjusted operating profit: ¥37.4B for 2Q (15.1% margin), down 9% year-over-year; 6-month adjusted operating profit: ¥50.6B, down 32% year-over-year.

• One-time restructuring costs related to headcount reduction estimated at JPY 30 billion over two years, with JPY 12 billion included in current forecasts.

• FDA remediation costs (JPY 10 billion) expected to be resolved within the fiscal year, normalizing SG&A ratios.

Outlook and guidance

• FY2026 revenue forecast: ¥998.0B, flat year-over-year, with 3% growth after FX adjustment; adjusted operating profit forecast: ¥157.0B (15.7% margin), down 9% year-over-year after FX adjustment.

• No inorganic growth (M&A, JVs, distribution deals) is included in the forecast, but such opportunities are actively pursued to accelerate growth.

• Guidance is considered conservative, with management emphasizing credibility and consistent delivery; upside potential exists if product launches and market recoveries outperform.

• Confidence in second-half performance is based on new product launches, commercial execution, and leading sales indicators.

• Full-year profit attributable to owners of parent forecast: ¥94.0B; EPS: ¥85; annual dividend forecast: ¥30/share, up ¥10/share; ¥50B share buyback planned.